Table 1.
Demographic characteristics of all adult patients prescribed imipenem-cilastatin, meropenem, or piperacillin-tazobactam during the study period.
| Characteristics | N (%) |
|---|---|
| Sex: | |
| Male | 1389 (50.9%) |
| Female | 1342 (49.1%) |
| Age (years) Mean ± SD | 55.5 ± 20.3 |
| Length of stay Median (range) | 14 (1–3185) |
| Allergy status: | |
| Documented drug allergy | 91 (3.3%) |
| Documented antimicrobial allergy | 48 (1.8%) |
| Co-morbidities: | |
| Diabetes mellitus | 1079 (39.5%) |
| Cardiovascular disease | 702 (25.7%) |
| Hypertension | 767 (28.1%) |
| Respiratory disease | 355 (13%) |
| Dyslipidaemia | 526 (19.3%) |
| Psychiatric disorder | 226 (8.3%) |
| Musculoskeletal disorder | 220 (8.1%) |
| Haematological disorder | 359 (13.1%) |
| Gastrointestinal disease | 232 (8.5%) |
| Liver disease | 154 (5.6%) |
| Neurological disorders | 303 (11.1%) |
| Thyroid disorder | 178 (6.5%) |
| Kidney disease | 365 (13.4%) |
| Cancer | 510 (18.7%) |
| Vitamin D deficiency | 215 (7.9%) |